These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 9894692)

  • 1. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature.
    Mrsny RJ
    J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate immunity and new adjuvants.
    Mutwiri G; Gerdts V; Lopez M; Babiuk LA
    Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
    Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
    Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvants and delivery systems for viral vaccines--mechanisms and potential.
    Jennings R; Simms JR; Heath AW
    Dev Biol Stand; 1998; 92():19-28. PubMed ID: 9554256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving vaccine performance with adjuvants.
    Vogel FR
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries.
    Walker RI
    Vaccine; 2005 May; 23(26):3369-85. PubMed ID: 15837361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of new vaccine technologies for the control of transboundary diseases.
    Swayne DE
    Dev Biol (Basel); 2004; 119():219-28. PubMed ID: 15742632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European union regulatory developments for new vaccine adjuvants and delivery systems.
    Sesardic D; Dobbelaer R
    Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants].
    Koprowski H
    Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.
    Innes EA; Vermeulen AN
    Parasitology; 2006; 133 Suppl():S145-68. PubMed ID: 17274844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the innate immune response with improved vaccine adjuvants.
    Pashine A; Valiante NM; Ulmer JB
    Nat Med; 2005 Apr; 11(4 Suppl):S63-8. PubMed ID: 15812492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.